而近期，《Nature Medicine》发表的一项突破性研究，为降血脂治疗带来了颠覆性进展—— 只需一针，即可实现终生降脂，低密度脂蛋白（LDL-C）降低70% ！这究竟是黑科技还是天方夜谭？本文将为您深度解析。

在肝脏中对PCSK9进行表观遗传编辑，旨在诱导DNA甲基化和沉默基因表达，在表达人类PCSK9基因的转基因小鼠和食蟹猴中实现了LDL胆固醇水平的长期降低。 靶向人类 PCSK9 的强效表观遗传编辑器：降低低密度脂蛋白胆固醇水平的新突破 近日，来自 Chroma Medicine 的 ...

前蛋白转化酶枯草溶菌素9(Proprotein Convertase Subtilisin/ Kexin Type 9, PCSK9)是调控低密度脂蛋白胆固醇(Low-Density Lipoprotein Cholesterol, LDL-C)代谢的决定性靶点。

Epigenetic editing is a promising method for gene regulation in vitro and in vivo, allowing precise control of gene ...

Precision is also using its ARCUS platform to develop a treatment to edit PCSK9, a gene that regulates ... enable precise editing of the DNA of a living organism, opening up the possibility ...

Epigenetic editing offers a different approach—modifying gene expression without altering the DNA sequence. The present study investigated the potential of epigenetic editing to silence PCSK9 ...

1 Lombardo and his team first looked into connecting protein fragments known to epigenetically silence genes to a DNA binding domain protein programmed to specifically bind Pcsk9. After testing the ...

Novartis released a new type of cholesterol-lowering medication that goes one step further by blocking the synthesis of PCSK9 in the first place. This drug, known as Leqvio, does not target DNA ...

Through base editing, drugs replace single nucleotide in the DNA strand with another ... It will look at the effects of VERVE-101 on levels of PCSK9 and LDL cholesterol (LDC-c) in the blood ...

A single treatment cut PCSK9 levels by 98% and showed a “substantial ... they did notice some minor impact on other parts of the DNA. But this didn’t change how the affected genes worked ...

A single application of this innovative therapy slashed PCSK9 levels by an incredible 98 ... there was a slight interaction with other parts of the DNA; however, this did not alter the functioning ...